Avalo Therapeutics (AVTX) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Avalo Therapeutics (AVTX) has outperformed Oculis (OCS) over the past year, losing 62.1% versus a loss of 63.3%. Over five years, OCS leads with a -27.3% price change compared with -99.9% for AVTX. Oculis is the larger company by market cap ($393.4 million vs $390.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | OCS |
|---|---|---|
| Share price | $6.76 | $7.06 |
| Market cap | $390.88M | $393.35M |
| 1-day change | +0.15% | -5.11% |
| YTD return | -62.78% | -64.65% |
| 1-year return | -62.09% | -63.34% |
| 5-year return | -99.89% | -27.29% |
| EPS (TTM) | $-2.26 | $-1.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $59.00K | — |
| Revenue growth (YoY) | -86.62% | — |
| Net income (latest FY) | $-78.26M | — |
| Operating margin | -123601.69% | — |
| Net margin | -132642.37% | — |
| 52-week high | $24.27 | $34.48 |
| 52-week low | $6.53 | $6.78 |
| Distance from 52-week high | -72.15% | -79.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +414.79% | +407.79% |
| Average volume | 1.80M | 272.83K |
| Shares outstanding | 57.82M | 55.72M |
| Employees | 33 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
AVTX vs OCS FAQ
Which is bigger, Avalo Therapeutics or Oculis?
Oculis (OCS) is larger, with a market capitalization of $393.35M compared with $390.88M for Avalo Therapeutics (AVTX).
Which stock has performed better over the past year, AVTX or OCS?
AVTX returned -62.09% over the past 12 months, compared with -63.34% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Oculis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.